Systematic evaluation of particle loss during handling in the percutaneous transluminal angioplasty for eight different drug-coated balloons

被引:14
作者
Heinrich, Andreas [1 ]
Engler, Martin S. [1 ]
Guettler, Felix V. [1 ]
Matthaeus, Christian [2 ]
Popp, Juergen [2 ,3 ,4 ]
Teichgraeber, Ulf K. -M. [1 ]
机构
[1] Friedrich Schiller Univ, Dept Radiol, Jena Univ Hosp, Klinikum 1, D-07747 Jena, Germany
[2] Leibniz Inst Photon Technol, D-07743 Jena, Germany
[3] Friedrich Schiller Univ Jena, Inst Phys Chem, D-07743 Jena, Germany
[4] Friedrich Schiller Univ Jena, Abbe Ctr Photon, D-07743 Jena, Germany
关键词
IN-STENT RESTENOSIS; PACLITAXEL; DELIVERY; TECHNOLOGY; DISEASE;
D O I
10.1038/s41598-020-74227-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Paclitaxel drug coated balloons (DCBs) should provide optimal drug transfer exclusively to the target tissue. The aim of this study was to evaluate the particle loss by handling during angioplasty. A robotic arm was developed for systematic and reproducible drug abrasion experiments. The contact force on eight different commercially available DCB types was gradually increased, and high-resolution microscopic images of the deflated and inflated balloons were recorded. Three types of DCBs were classified: no abrasion of the drug in both statuses (deflated and inflated), significant abrasion only in the inflated status, and significant abrasion in both statuses. Quantitative measurements via image processing confirmed the qualitative classification and showed changes of the drug area between 2.25 and 45.73% (13.28 +/- 14.29%) in the deflated status, and between 1.66 and 40.41% (21.43 +/- 16.48%) in the inflated status. The structures and compositions of the DCBs are different, some are significantly more susceptible to drug loss. Particle loss by handling during angioplasty leads to different paclitaxel doses in the target regions for same DCB types. Susceptibility to involuntary drug loss may cause side effects, such as varying effective paclitaxel doses, which may explain variations in studies regarding the therapeutic outcome.
引用
收藏
页数:10
相关论文
共 30 条
[1]   Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment [J].
Bausback, Yvonne ;
Willfort-Ehringer, Andrea ;
Sievert, Horst ;
Geist, Volker ;
Lichtenberg, Michael ;
Del Giudice, Costantino ;
Sauguet, Antoine ;
Diaz-Cartelle, Juan ;
Marx, Claudia ;
Stroebel, Armin ;
Schult, Ingolf ;
Scheinert, Dierk .
JOURNAL OF ENDOVASCULAR THERAPY, 2017, 24 (04) :459-467
[2]  
Brandt-Wunderlich Christoph, 2017, Current Directions in Biomedical Engineering, V3, P465, DOI 10.1515/cdbme-2017-0098
[3]   Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon The ILLUMENATE European Randomized Clinical Trial 2-Year Results [J].
Brodmann, Marianne ;
Werner, Martin ;
Meyer, Dirk-Roelfs ;
Reimer, Peter ;
Krueger, Karsten ;
Granada, Juan F. ;
Jaff, Michael R. ;
Schroeder, Henrik .
JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (23) :2357-2364
[4]   Drug-coated balloon therapy in coronary and peripheral artery disease [J].
Byrne, Robert A. ;
Joner, Michael ;
Alfonso, Fernando ;
Kastrati, Adnan .
NATURE REVIEWS CARDIOLOGY, 2014, 11 (01) :13-23
[5]  
Cohen J., 1988, STAT POWER ANAL BEHA, DOI 10.4324/9780203771587
[6]  
Dalgleish C, 2012, ICD 10 PCS CODING SY
[7]   In-Stent Restenosis in the Drug-Eluting Stent Era [J].
Dangas, George D. ;
Claessen, Bimmer E. ;
Caixeta, Adriano ;
Sanidas, Elias A. ;
Mintz, Gary S. ;
Mehran, Roxana .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (23) :1897-1907
[8]   Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis [J].
Gongora, Carlos A. ;
Shibuya, Masahiko ;
Wessler, Jeffrey D. ;
McGregor, Jenn ;
Tellez, Armando ;
Cheng, Yanping ;
Conditt, Gerard B. ;
Kaluza, Greg L. ;
Granada, Juan F. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (08) :1115-1123
[9]   Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial [J].
Jeger, Raban V. ;
Farah, Ahmed ;
Ohlow, Marc-Alexander ;
Mangner, Norman ;
Moebius-Winkler, Sven ;
Leibundgut, Gregor ;
Weilenmann, Daniel ;
Woehrle, Jochen ;
Richter, Stefan ;
Schreiber, Matthias ;
Mahfoud, Felix ;
Linke, Axel ;
Stephan, Frank-Peter ;
Mueller, Christian ;
Rickenbacher, Peter ;
Coslovsky, Michael ;
Gilgen, Nicole ;
Osswald, Stefan ;
Kaiser, Christoph ;
Scheller, Bruno .
LANCET, 2018, 392 (10150) :849-856
[10]   Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J].
Katsanos, Konstantinos ;
Spiliopoulos, Stavros ;
Kitrou, Panagiotis ;
Krokidis, Miltiadis ;
Karnabatidis, Dimitrios .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (24)